Stopped: COVID-19 general concerns
Vestibular disorders are among the most common causes of disability in society and affect over 50% of the population over the age of 65 and a significant percentage of the younger population. Acute unilateral vestibulopathy (AUV) is easy to diagnose and is commonly treated with physical therapy exercises called vestibular rehabilitation. But due to the discomfort experienced during AUV, patients can't usually comply with the treatment plan prescribed by their healthcare provider. In this study, the investigators propose the use of an adjuvant device, the OtoBand, to improve balance, gait, reduce vertigo, and nausea in participants with AUV. Participants enrolled will undergo three vestibular tests batteries: one baseline, one with the OtoBand set at an effective power, and one with the placebo device set at low power. Neither participants nor investigator will know which device is effective and which is placebo. The OtoBand will be set at two different effective power levels. Which power level the participant will receive is randomized and unknown to the participant or investigator.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in vestibular function as measured by Functional Gait Assessment
Timeframe: Three tests over 30 minutes - During 1-day visit at the University of Miami Health System.
Change in vestibular function as measured by Dizziness Handicap Inventory
Timeframe: Three times immediately following FGA testing - During 1-day visit at the University of Miami Health System.
Change in vestibular function as measured by I-PAS testing
Timeframe: Three tests over one hour - During the 1-day visit at the University of Miami Health System.